Kevin Pham, MD
Nephrology · Orange, CANPI 1477623635
Payments from drug & device makers
Across 1,173 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Amgen$2K
- OPKO Pharmaceuticals, LLC$2K
- Akebia Therapeutics Inc$2K
- Mallinckrodt Hospital Products Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $9K from 33 others
What the payments were for
- Food & beverage$23,41399%
- Education$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 269 | $5,979 |
| Amgen(2 entities) | 102 | $1,994 |
| OPKO Pharmaceuticals, LLC | 111 | $1,729 |
| Akebia Therapeutics Inc | 92 | $1,702 |
| Mallinckrodt Hospital Products Inc. | 79 | $1,575 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,461 |
| Travere Therapeutics, Inc. | 67 | $1,418 |
| Vifor Pharma, Inc. | 61 | $1,126 |
| Fresenius USA Marketing, Inc. | 61 | $1,059 |
| Ardelyx, Inc. | 33 | $689 |
| Calliditas Therapeutics US Inc. | 27 | $632 |
| Boehringer Ingelheim | 28 | $522 |
| GSK | 32 | $518 |
| Novartis | 17 | $371 |
| Bayer | 14 | $320 |
| Lilly USA, LLC | 23 | $295 |
| Novo Nordisk | 8 | $294 |
| Arbor Pharmaceuticals, Inc. | 12 | $204 |
| Lundbeck LLC | 10 | $191 |
| Mallinckrodt Enterprises LLC | 10 | $184 |
| Apellis Pharmaceuticals, Inc. | 6 | $151 |
| Scpharmaceuticals Inc. | 5 | $144 |
| Daiichi Sankyo Inc. | 7 | $137 |
| Veloxis Pharmaceuticals, Inc. | 3 | $128 |
| Sanofi | 5 | $123 |
| Aurinia Pharma U.S., Inc. | 5 | $92 |
| Medline Industries LP | 1 | $83 |
| Merck | 3 | $78 |
| Chiesi USA, Inc. | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| UCB, Inc. | 1 | $38 |
| Teleflex LLC | 1 | $33 |
| Mannkind Corporation | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Smith+Nephew | 1 | $23 |
| Abbott | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,531 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 101 | $262,385 |
| FarxigaDapagliflozin Propanediol | 353 | $216,339 |
| KerendiaFinerenone | 277 | $181,265 |
| VeltassaPatiromer Calcium Sorbitex | 163 | $139,274 |
| AuryxiaFerric Citrate | 45 | $112,325 |
| RayaldeeCalcifediol | 55 | $111,534 |
| LokelmaSodium Zirconium Cyclosilicate | 170 | $103,735 |
| XphozahTenapanor Hcl | 30 | $79,052 |
| Sevelamer Carbonate | 252 | $78,692 |
| JardianceEmpagliflozin | 118 | $72,032 |
| ProcritEpoetin Alfa | 84 | $70,458 |
| DapagliflozinDapagliflozin Propanediol | 120 | $59,011 |
| Calcium Acetate | 199 | $23,805 |
| EliquisApixaban | 15 | $19,824 |
| RetacritEpoetin Alfa-Epbx | 72 | $18,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $5,979 | $320,073523 claims |
| Fresenius USA Marketing, Inc.Velphoro | $1,059 | $262,385101 claims |
| BayerKerendia | $320 | $181,265277 claims |
| Akebia Therapeutics IncAuryxia | $1,702 | $112,32545 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,729 | $111,53455 claims |
| Boehringer IngelheimJardiance | $522 | $72,032118 claims |
| Johnson & JohnsonProcrit | $14 | $70,45884 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Orange
- Stephanie CheungOrange$1.1M
- Yasir QaziOrange$993K
- Ramy HannaOrange$923K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.